The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The trial will enroll up to 42 patients in Finland across four cohorts
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Elanco expects Befrena to launch in the US in the first half of 2026
Once finalized, cough syrups will no longer be available for over-the-counter sale
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Subscribe To Our Newsletter & Stay Updated
